.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has actually chosen Eli Lilly (NYSE: LLY) as its best biopharma pick for 2025 and ranked yet another 9 names in the area as overweight. The financial investment bank pointed out in a keep in mind that it continues to believe “diabesity is set to come to be.